Lundbeck’s bexicaserin receives Breakthrough Therapy Designation in China for the treatment of seizures in severe rare epilepsies

  • Accelerated pathway underscores urgent need for innovative solutions for patients with devastating, childhood-onset epilepsies
  • Novel 5HT2C mechanism designed to reduce…

Continue Reading